Trial Profile

A Multicenter, Randomized, Double-Blind and Open-label Phase III Study To Compare The Efficacy And Safety Of Eltrombopag With Placebo In Chinese Chronic ITP Patients

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eltrombopag (Primary)
Indications Idiopathic thrombocytopenic purpura
Focus Registrational; Therapeutic Use
Sponsors GSK; Novartis; Novartis Pharmaceuticals

Most Recent Events

18 Dec 2018 Status changed from active, no longer recruiting to completed.
04 Dec 2018 Results of stage 2 part of this study assessing efficacy and tolerability of Eltrombopag, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
17 Apr 2018 Planned End Date changed from 31 Mar 2018 to 15 Nov 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com